Proteomic characterization of the colorectal cancer response to chemoradiation and targeted therapies

ABSTRACT: Herein, we assembled a cohort composed of 254 CRC patients, including discovery cohort (N = 124) and validation cohort (N = 130), which received either chemotherapy (mainly FOLFOX therapy), chemoradiotherapy (mainly FOLFOX combined with radiotherapy), or targeted combination therapy (mainly FOLFOX combined with cetuximab).

ORGANISM(S): Homo Sapiens

SUBMITTER: Chen Ding  

PROVIDER: PXD046566 | iProX | Mon Oct 30 00:00:00 GMT 2023

REPOSITORIES: iProX